BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22682760)

  • 1. Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer.
    Chen X; Yun J; Fei F; Yi J; Tian R; Li S; Gan X
    Pathol Res Pract; 2012 Aug; 208(8):437-43. PubMed ID: 22682760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial--mesenchymal transition.
    Chen SC; Kung ML; Hu TH; Chen HY; Wu JC; Kuo HM; Tsai HE; Lin YW; Wen ZH; Liu JK; Yeh MH; Tai MH
    J Pathol; 2012 Oct; 228(2):158-69. PubMed ID: 22247069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma.
    Yamamoto S; Tomita Y; Hoshida Y; Takiguchi S; Fujiwara Y; Yasuda T; Doki Y; Yoshida K; Aozasa K; Nakamura H; Monden M
    Clin Cancer Res; 2006 Jan; 12(1):117-22. PubMed ID: 16397032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors.
    Hu TH; Lin JW; Chen HH; Liu LF; Chuah SK; Tai MH
    Dis Colon Rectum; 2009 Feb; 52(2):319-26. PubMed ID: 19279430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.
    Iwasaki T; Nakagawa K; Nakamura H; Takada Y; Matsui K; Kawahara K
    Oncol Rep; 2005 Jun; 13(6):1075-80. PubMed ID: 15870924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.
    Ren H; Tang X; Lee JJ; Feng L; Everett AD; Hong WK; Khuri FR; Mao L
    J Clin Oncol; 2004 Aug; 22(16):3230-7. PubMed ID: 15310766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer.
    Lin YW; Li CF; Chen HY; Yen CY; Lin LC; Huang CC; Huang HY; Wu PC; Chen CH; Chen SC; Tai MH
    Oral Oncol; 2012 Jul; 48(7):629-35. PubMed ID: 22361040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
    Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
    Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
    Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
    Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of MAC30 protein is related to survival and clinicopathological variables in breast cancer.
    Xiao M; Li H; Yang S; Huang Y; Jia S; Wang H; Wang J; Li Z
    J Surg Oncol; 2013 Apr; 107(5):456-62. PubMed ID: 22996179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma.
    Yamamoto S; Tomita Y; Hoshida Y; Morii E; Yasuda T; Doki Y; Aozasa K; Uyama H; Nakamura H; Monden M
    Ann Surg Oncol; 2007 Jul; 14(7):2141-9. PubMed ID: 17473954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer.
    Uyama H; Tomita Y; Nakamura H; Nakamori S; Zhang B; Hoshida Y; Enomoto H; Okuda Y; Sakon M; Aozasa K; Kawase I; Hayashi N; Monden M
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6043-8. PubMed ID: 17062679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma.
    Yoshida K; Tomita Y; Okuda Y; Yamamoto S; Enomoto H; Uyama H; Ito H; Hoshida Y; Aozasa K; Nagano H; Sakon M; Kawase I; Monden M; Nakamura H
    Ann Surg Oncol; 2006 Feb; 13(2):159-67. PubMed ID: 16411141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.
    Dolled-Filhart M; Camp RL; Kowalski DP; Smith BL; Rimm DL
    Clin Cancer Res; 2003 Feb; 9(2):594-600. PubMed ID: 12576423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and hepatoma-derived growth factor expression and their clinicopathological association with Ewing family tumour.
    Yang Y; Zhen T; Zhang F; Dai S; Kang L; Liang Y; Xue L; Han A
    J Clin Pathol; 2014 Mar; 67(3):235-42. PubMed ID: 24072730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis.
    Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
    J Clin Pathol; 2012 Jan; 65(1):36-40. PubMed ID: 22049226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of HDGF and its implication in stage I non-small cell lung cancer].
    Zhou SJ; Xu SF; Zhang HQ; Liu ZD
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):927-30. PubMed ID: 18478933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.